LifeBiotic Launches Randomized Phase 2 Trial of Botanical Drug Candidate for Bladder Cancer Recurrence Prevention

Published early clinical findings showed a reduction of approximately 75% in recurrence of bladder cancer following LCS103 use compared with patients’ prior recurrence history. The promising botanical formulation is now undergoing randomized evaluation at Rambam, Northern Israel’s largest…